Table 1 Clinical characteristics and laboratory parameters of IgAN and IgAVN patients
IgAN | IgAVN | P value | |
|---|---|---|---|
Gender (male/ female, n) | 119/134 | 33/38 | 0.934 |
Age (years) | 35.1 ± 11.9 | 32.3 ± 15.9 | 0.106 |
Hypertension (n, %) | 67 (26.5%) | 13 (18.3%) | 0.158 |
Rash (n, %) | 5 (2%) | 71 (100%) | 0.001 |
Abdominal symptoms (n, %) | 5 (2%) | 14 (19.7%) | 0.000 |
Joint pain (n, %) | 0 (0%) | 18 (25.4%) | 0.000 |
Oedema (n, %) | 44 (17.4%) | 4 (5.6%) | 0.013 |
Gross haematuria (n, %) | 48 (19.0%) | 3 (4.2%) | 0.002 |
Microscopic haematuria (n, %) | 234 (93.2%) | 67 (94.4%) | 0.731 |
Dysmorphic RBC > 80% (n, %) | 226 (94.96%) | 60 (92.31%) | 0.604 |
Months from onset to biopsy | 13.5 ± 26.6 | 10.2 ± 31.6 | 0.007 |
WBC (*10^9/L) | 6.5 ± 2.1 | 8.1 ± 3.0 | < 0.001 |
Hb (g/L) | 134 ± 22.2 | 137.2 ± 19.2 | 0.110 |
PLT (*10^9/L) | 235.3 ± 65.9 | 223.9 ± 67.0 | 0.303 |
Urinary protein (g/24 h) | 2.1 ± 0.6 | 1.997 ± 0.3 | 0.842 |
Urinary Kap (mg/L) | 35.1 ± 43.9 | 63.8 ± 157.1 | 0.023 |
Urinary Lam (mg/L) | 19.5 ± 31.8 | 35.7 ± 86.3 | 0.030 |
TP (g/L) | 66.8 ± 9.1 | 64.4 ± 8.7 | 0.083 |
ALB (g/L) | 39.5 ± 6.3 | 38.55 ± 6.5 | 0.230 |
Scr (µmol/L) | 92.3 ± 94.7 | 68.9 ± 69.2 | 0.015 |
UA (µmol/L) | 355 ± 98.6 | 300.4 ± 90.8 | < 0.001 |
eGFR(mL/min/1.73m2) | 99.1 ± 35.2 | 123.4 ± 41.8 | < 0.001 |
IgA (g/L) | 3.2 ± 1.3 | 3.1 ± 1.3 | 0.508 |
IgE (IU/mL) | 149.3 ± 359.9 | 79.2 ± 128.4 | 0.010 |
Treatment | |||
ACEIs/ARBs alone (n, %) | 69 (33.3%) | 5 (7.6%) | < 0.001 |
Prednisone (n, %) | 116 (56%) | 52 (78.8%) | |
Prednisone + MMF (n, %) | 11 (0.53%) | 3 (4.5%) | |
Prednisone + CTX (n, %) | 11 (0.53%) | 6 (9.1%) |